Neoplasms Pancreatic Clinical Trial
Official title:
PRIMUS 001: An Adaptive Phase II Study of FOLFOX-A (FOLFOX and Nab-paclitaxel) Versus AG (Nab-paclitaxel and Gemcitabine) in Patients With Metastatic Pancreatic Cancer, With Integrated Biomarker Evaluation
This study is comparing two combinations of chemotherapy treatments in patients with metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half will receive AG. Treatment will continue until progression or patient/clinican decision or intolerable toxicity.
PRIMUS 001 is a multicentre, randomised, open label, two arm, phase II interventional trial with pre-clinical and translational work including in-depth molecular profiling and biomarker discovery/development. The primary objective is to look at the efficacy of FOLFOX-A compared to AG in all comers and in a biomarker positive group using progression free survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT05547074 -
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
|
||
| Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT02973217 -
Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04161417 -
Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer
|
N/A | |
| Terminated |
NCT03187587 -
Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
|
N/A | |
| Terminated |
NCT04176952 -
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05669482 -
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03535727 -
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04566614 -
Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
|
||
| Completed |
NCT06118125 -
Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
|
||
| Active, not recruiting |
NCT03678883 -
9-ING-41 in Patients With Advanced Cancers
|
Phase 2 |